title: Gastroparesis: what is the current state-of-the-art for evaluation and medical management? What are the results?
abstract: Gastroparesis is a chronic motility disorder that leads to delayed gastric emptying and negatively impacts morbidity, mortality, and quality of life. This paper provides an overview of the pathophysiology leading to symptoms in gastroparesis, discusses tests for diagnosis, and examines the evidence behind different treatment options for gastroparesis. Although delayed gastric emptying is the cardinal finding in gastroparesis, other physiologic abnormalities may contribute to the pathogenesis of symptoms. Gastric emptying scintigraphy is considered the gold standard for the diagnosis of gastroparesis but novel tests are currently available. Although metoclopramide is the only FDA approved medication to treat gastroparesis, alternative therapeutic options are available and should be tailored according to symptoms as well as physiologic abnormalities.
authors.affiliation: University of Vermont, 111 Colchester Ave, MS 320FL4, Burlington, VT 05401, USA. allen.lee@vtmednet.org
authors.forename: Allen
authors.initials: A
authors.lastname: Lee
mesh_terms: D001905:Botulinum Toxins / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004035:Diet Therapy; D004294:Domperidone / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D018589:Gastroparesis / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D016540:Smoking Cessation
chemical_list: D005765:Gastrointestinal Agents; D004294:Domperidone; D004917:Erythromycin; D001905:Botulinum Toxins; D008787:Metoclopramide